Whereas NAC combined with HER2-targeted agents is considered suitable treatment for cases of HER2 breast cancer, it appears that NAC regimens should be reconsidered for the treatment of non-HER2 cases of IHC/FISH HER2 + breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.